Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
99.87
+1.62 (1.65%)
At close: Jun 24, 2026, 4:00 PM EDT
99.92
+0.05 (0.05%)
After-hours: Jun 24, 2026, 6:16 PM EDT
Kymera Therapeutics Market Cap
Kymera Therapeutics has a market cap or net worth of $8.22 billion as of June 24, 2026. Its market cap has increased by 167.50% in one year.
Market Cap
8.22B
Enterprise Value
6.75B
1-Year Change
167.50%
Ranking
Category
Stock Price
$99.87
Market Cap Chart
Since the IPO on August 21, 2020, Kymera Therapeutics's market cap has increased from $834.48M to $8.22B, an increase of 884.45%. That is a compound annual growth rate of 47.90%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 24, 2026 | 8.22B | 31.97% |
| Dec 31, 2025 | 6.22B | 138.91% |
| Dec 31, 2024 | 2.61B | 84.43% |
| Dec 29, 2023 | 1.41B | 3.16% |
| Dec 30, 2022 | 1.37B | -57.98% |
| Dec 31, 2021 | 3.26B | 18.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Aug 21, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Spyre Therapeutics | 8.71B |
| Bio-Techne | 8.71B |
| Corcept Therapeutics | 8.56B |
| Praxis Precision Medicines | 8.46B |
| Halozyme Therapeutics | 8.18B |
| ABIVAX Société Anonyme | 7.83B |
| Immunovant | 7.82B |
| TG Therapeutics | 7.71B |